HRP20040070A2 - Use of lh in controlled ovarian hyperstimulation - Google Patents
Use of lh in controlled ovarian hyperstimulation Download PDFInfo
- Publication number
- HRP20040070A2 HRP20040070A2 HR20040070A HRP20040070A HRP20040070A2 HR P20040070 A2 HRP20040070 A2 HR P20040070A2 HR 20040070 A HR20040070 A HR 20040070A HR P20040070 A HRP20040070 A HR P20040070A HR P20040070 A2 HRP20040070 A2 HR P20040070A2
- Authority
- HR
- Croatia
- Prior art keywords
- fsh
- day
- patient
- administration
- hours
- Prior art date
Links
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 title description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 170
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 170
- 229940040129 luteinizing hormone Drugs 0.000 claims description 170
- 230000000638 stimulation Effects 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 48
- 230000004044 response Effects 0.000 claims description 42
- 239000003098 androgen Substances 0.000 claims description 37
- 229940011871 estrogen Drugs 0.000 claims description 31
- 239000000262 estrogen Substances 0.000 claims description 31
- 238000005259 measurement Methods 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 11
- 229960005309 estradiol Drugs 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 229930182833 estradiol Natural products 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 5
- 229960005471 androstenedione Drugs 0.000 claims description 5
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims description 5
- 230000002045 lasting effect Effects 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 94
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 94
- 229940028334 follicle stimulating hormone Drugs 0.000 description 94
- 239000012071 phase Substances 0.000 description 39
- 238000002347 injection Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 230000016087 ovulation Effects 0.000 description 19
- 210000000287 oocyte Anatomy 0.000 description 15
- 239000000556 agonist Substances 0.000 description 10
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 9
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 8
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 102000006771 Gonadotropins Human genes 0.000 description 6
- 108010086677 Gonadotropins Proteins 0.000 description 6
- 229940030486 androgens Drugs 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 6
- 239000002622 gonadotropin Substances 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 102000014654 Aromatase Human genes 0.000 description 5
- 108010078554 Aromatase Proteins 0.000 description 5
- 229940094892 gonadotropins Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000003684 theca cell Anatomy 0.000 description 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 239000002474 gonadorelin antagonist Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 230000029849 luteinization Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- 101800001415 Bri23 peptide Proteins 0.000 description 3
- 101800000655 C-terminal peptide Proteins 0.000 description 3
- 102400000107 C-terminal peptide Human genes 0.000 description 3
- 230000001548 androgenic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000008217 follicular development Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 229940046989 clomiphene citrate Drugs 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000012502 diagnostic product Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 108010055450 with HCG C-terminal peptide human follicle stimulating hormone Proteins 0.000 description 2
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- -1 Azaline B Chemical compound 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010068042 Premature ovulation Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 229940127233 azaline B Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960005064 buserelin acetate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108010067479 inhibin B Proteins 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 description 1
- 108010083551 iturelix Proteins 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940086546 synarel Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01307755 | 2001-09-12 | ||
| PCT/GB2002/004147 WO2003022301A2 (fr) | 2001-09-12 | 2002-09-12 | Utilisation de l'hormone luteinisante (lh) dans l'hypersimulation ovarienne controlee (hoc) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040070A2 true HRP20040070A2 (en) | 2004-10-31 |
Family
ID=8182260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040070A HRP20040070A2 (en) | 2001-09-12 | 2004-01-23 | Use of lh in controlled ovarian hyperstimulation |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7341989B2 (fr) |
| EP (1) | EP1434600B1 (fr) |
| JP (1) | JP2005504072A (fr) |
| KR (1) | KR20040032953A (fr) |
| CN (1) | CN1302806C (fr) |
| AR (1) | AR036591A1 (fr) |
| AT (1) | ATE427755T1 (fr) |
| AU (1) | AU2002331939B2 (fr) |
| BR (1) | BR0212502A (fr) |
| CA (1) | CA2457067A1 (fr) |
| CY (1) | CY1110487T1 (fr) |
| DE (1) | DE60231892D1 (fr) |
| DK (1) | DK1434600T3 (fr) |
| EA (1) | EA009210B1 (fr) |
| ES (1) | ES2322136T3 (fr) |
| HK (1) | HK1067866A1 (fr) |
| HR (1) | HRP20040070A2 (fr) |
| IL (1) | IL160781A0 (fr) |
| ME (1) | MEP38808A (fr) |
| MX (1) | MXPA04002125A (fr) |
| NO (1) | NO327154B1 (fr) |
| PL (1) | PL205472B1 (fr) |
| PT (1) | PT1434600E (fr) |
| RS (1) | RS51505B (fr) |
| SI (1) | SI1434600T1 (fr) |
| UA (1) | UA78970C2 (fr) |
| WO (1) | WO2003022301A2 (fr) |
| ZA (1) | ZA200401008B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1684737A (zh) * | 2002-06-07 | 2005-10-19 | 阿雷斯贸易股份有限公司 | 控制性超排卵方法及该方法使用的药物试剂盒 |
| US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| CN102296047B (zh) * | 2011-08-13 | 2013-03-13 | 新疆农垦科学院 | 利用羔羊超排卵母细胞生产体外胚胎的方法 |
| US20150272622A1 (en) | 2011-12-22 | 2015-10-01 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
| US9216037B2 (en) | 2013-06-21 | 2015-12-22 | Previvo Genetics, Llc | Uterine lavage for embryo retrieval |
| US9282995B2 (en) * | 2011-12-22 | 2016-03-15 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
| EP2968391A1 (fr) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Molécules polynucléotidiques à longue durée de vie |
| RU2629871C1 (ru) * | 2016-03-22 | 2017-09-04 | Сергей Михайлович Юдин | Препарат для стимуляции фолликулогенеза и способ его применения |
| IT202000022015A1 (it) * | 2020-09-18 | 2022-03-18 | Marca Antonio La | Nuovo uso dell'ormone luteinizzante |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4589402A (en) | 1984-07-26 | 1986-05-20 | Serono Laboratories, Inc. | Method of in vitro fertilization |
| IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
| CA2372714A1 (fr) * | 1999-05-07 | 2000-11-16 | Stephen Franks | Gonadotrophines |
-
2002
- 2002-09-12 JP JP2003526429A patent/JP2005504072A/ja active Pending
- 2002-09-12 PT PT02767637T patent/PT1434600E/pt unknown
- 2002-09-12 US US10/487,423 patent/US7341989B2/en not_active Expired - Fee Related
- 2002-09-12 CN CNB028175743A patent/CN1302806C/zh not_active Expired - Fee Related
- 2002-09-12 PL PL367343A patent/PL205472B1/pl unknown
- 2002-09-12 KR KR10-2004-7002589A patent/KR20040032953A/ko not_active Application Discontinuation
- 2002-09-12 AU AU2002331939A patent/AU2002331939B2/en not_active Ceased
- 2002-09-12 EA EA200400428A patent/EA009210B1/ru not_active IP Right Cessation
- 2002-09-12 ME MEP-388/08A patent/MEP38808A/xx unknown
- 2002-09-12 RS YUP-212/04A patent/RS51505B/sr unknown
- 2002-09-12 EP EP02767637A patent/EP1434600B1/fr not_active Revoked
- 2002-09-12 ES ES02767637T patent/ES2322136T3/es not_active Expired - Lifetime
- 2002-09-12 WO PCT/GB2002/004147 patent/WO2003022301A2/fr active Application Filing
- 2002-09-12 MX MXPA04002125A patent/MXPA04002125A/es active IP Right Grant
- 2002-09-12 BR BR0212502-1A patent/BR0212502A/pt not_active Application Discontinuation
- 2002-09-12 IL IL16078102A patent/IL160781A0/xx unknown
- 2002-09-12 AT AT02767637T patent/ATE427755T1/de active
- 2002-09-12 AR ARP020103455A patent/AR036591A1/es not_active Application Discontinuation
- 2002-09-12 SI SI200230815T patent/SI1434600T1/sl unknown
- 2002-09-12 CA CA002457067A patent/CA2457067A1/fr not_active Withdrawn
- 2002-09-12 DE DE60231892T patent/DE60231892D1/de not_active Expired - Lifetime
- 2002-09-12 DK DK02767637T patent/DK1434600T3/da active
- 2002-12-09 UA UA2004031858A patent/UA78970C2/uk unknown
-
2004
- 2004-01-23 HR HR20040070A patent/HRP20040070A2/hr not_active Application Discontinuation
- 2004-02-06 ZA ZA2004/01008A patent/ZA200401008B/en unknown
- 2004-03-08 NO NO20040990A patent/NO327154B1/no not_active IP Right Cessation
-
2005
- 2005-02-22 HK HK05101453A patent/HK1067866A1/xx not_active IP Right Cessation
-
2009
- 2009-06-30 CY CY20091100694T patent/CY1110487T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shoham et al. | Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients | |
| Filicori et al. | The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction | |
| JP2005501918A (ja) | 制御下の過排卵刺激におけるｈＣＧの使用 | |
| HRP20040070A2 (en) | Use of lh in controlled ovarian hyperstimulation | |
| Zafeiriou et al. | The role of gonadotropins in follicular development and their use in ovulation induction protocols for assisted reproduction | |
| EP1425033B1 (fr) | Utilisation de hcg et de lh in dans l'hyperstimulation ovarienne controlee | |
| AU2002331939A1 (en) | Use of LH in controlled ovarian hyperstimulation | |
| US7815912B2 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| Blumenfeld et al. | Synergistic Effect of Growth Hormone and Gonadotropins in Achieving Conception in “Clonidine‐Negative” Patients with Unexplained Infertility a | |
| Fauser | Follicular development and oocyte maturation in hypogonadotrophic women employing recombinant follicle-stimulating hormone: the role of oestradiol | |
| Yuen et al. | Induction of ovulation with exogenous gonadotropins in anovulatory infertile women | |
| AU2002324183B2 (en) | Use of hCG and LH in controlled ovarian hyperstimulation | |
| Meridis et al. | Drugs in reproductive medicine | |
| Allahbadia et al. | Induction Protocols of the 2000s Using r-hLH and r-hCG | |
| Amesse et al. | Recombinant Gonadotropin Use for Ovulation Induction in Polycystic Ovary Syndrome | |
| AU2002324183A1 (en) | Use of hCG and LH in controlled ovarian hyperstimulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| PPPP | Transfer of rights |
Owner name: LABORATOIRES SERONO SA, CH |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20130806 Year of fee payment: 12 |
|
| ODBI | Application refused |